International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement

Autoimmunity Reviews

Volumn 16, Issue 5, 2017, Pages 523-541

  Zignego, Anna Linda ^a   Ramos Casals, Manuel ^b   Ferri, Clodoveo ^c   Saadoun, David ^n,o,p   Arcaini, Luca ^d   Roccatello, Dario ^e,f   Antonelli, Alessandro ^g   Desbois, Anne Claire ^n,o,p   Comarmond, Cloe ^n,o,p   Gragnani, Laura ^a   Casato, Milvia ^h   Lamprecht, Peter ⁱ   Mangia, Alessandra ^j   Tzioufas, Athanasios G ^k   Younossi, Zobair M ^l,m   Cacoub, Patrice ^n,o,p  

^a UNIVERSITY OF FLORENCE   (Italy)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ Klinikum Bad Bramstedt   (Germany)

^j CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^k UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^l INOVA FAIRFAX HOSPITAL   (United States)

^m BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

ⁿ SORBONNE UNIVERSITÉ   (France)

^o Unit of Dermatology   (France)

^p PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

Anti HCV therapy; Extrahepatic manifestations of HCV; Hepatitis C virus (HCV); Non etiological therapy

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; CHLOROQUINE; CYCLOSPORIN; ETRETIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; METHOTREXATE; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR;

ARTHRITIS; CRYOGLOBULINEMIC VASCULITIS; HEPATITIS C; HEPATITIS C EXTRAHEPATIC MANIFESTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LICHEN PLANUS; LYMPHOMA; MENTAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT CARE; PHLEBOTOMY; PHYSICAL DISEASE; PORPHYRIA CUTANEA TARDA; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SJOEGREN SYNDROME; SUNLIGHT PROTECTION; THYROID DISEASE; VASCULITIS; COMPLICATION; HEALTH CARE PLANNING; HEPACIVIRUS; METABOLISM;

ANTIVIRAL AGENTS; HEALTH PLANNING GUIDELINES; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 85016080037     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.03.004     Document Type: Review

References (285)

1. [1] Zignego, A.L., Ferri, C., Pileri, S.A., Caini, P., Bianchi, F.B., Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 39 (2007), 2–17.
2. [2] Backus, L.I., Boothroyd, D.B., Phillips, B.R., Belperio, P., Halloran, J., Mole, L.A., A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 9 (2011), 509–516, e1.
3. [3] El-Kamary, S.S., Jhaveri, R., Shardell, M.D., All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 53 (2011), 150–157.
4. [4] Harris, H.E., Ramsay, M.E., Andrews, N.J., Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure. Epidemiol Infect 134 (2006), 472–477.
5. [5] Hsu, Y.C., Lin, J.T., Ho, H.J., Kao, Y.H., Huang, Y.T., Hsiao, N.W., et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 59 (2014), 1293–1302.
6. [6] Lee, M.H., Yang, H.I., Lu, S.N., Jen, C.L., You, S.L., Wang, L.Y., et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 206 (2012), 469–477.
7. [7] Uto, H., Stuver, S.O., Hayashi, K., Kumagai, K., Sasaki, F., Kanmura, S., et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology 50 (2009), 393–399.
8. [8] Maasoumy, B., Wedemeyer, H., Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 26 (2012), 401–412.
9. [9] Omland, L.H., Jepsen, P., Krarup, H., Schonning, K., Lind, B., Kromann-Andersen, H., et al. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol 9 (2011), 71–78.
10. [10] Kawamura, Y., Ikeda, K., Arase, Y., Yatsuji, H., Sezaki, H., Hosaka, T., et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 120 (2007), 1034–1041.
11. [11] Adinolfi, L.E., Zampino, R., Restivo, L., Lonardo, A., Guerrera, B., Marrone, A., et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol 20 (2014), 3410–3417.
12. [12] Cacoub, P., Gragnani, L., Comarmond, C., Zignego, A.L., Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 46:Suppl. 5 (2014), S165–S173.
13. [13] Ferri, C., Zignego, A.L., Longombardo, G., Monti, M., La Civita, L., Lombardini, F., et al. Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients. Infection 21 (1993), 93–97.
14. [14] Misiani, R., Bellavita, P., Fenili, D., Vicari, O., Marchesi, D., Sironi, P.L., et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330 (1994), 751–756.
15. [15] Adinolfi, L.E., Utili, R., Zampino, R., Ragone, E., Mormone, G., Ruggiero, G., Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia. Eur J Gastroenterol Hepatol 9 (1997), 1067–1072.
16. [16] Mazzaro, C., Monti, G., Saccardo, F., Zignego, A.L., Ferri, C., De Vita, S., et al. Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. Clin Exp Rheumatol 29 (2011), 933–941.
17. [17] Gragnani, L., Fognani, E., Piluso, A., Boldrini, B., Urraro, T., Fabbrizzi, A., et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology 61 (2015), 1145–1153.
18. [18] Banerjee, D., Reddy, K.R., Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther 43 (2016), 674–696.
19. [19] Ferri, C., Ramos-Casals, M., Zignego, A.L., Arcaini, L., Roccatello, D., Antonelli, A., et al. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev 15 (2016), 1145–1160.
20. [20] Zignego, A.L., Ferri, C., Giannini, C., La Civita, L., Careccia, G., Longombardo, G., et al. Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: evidence for a pathogenetic role. Arch Virol 142 (1997), 545–555.
21. [21] Ferri, C., La Civita, L., Longombardo, G., Greco, F., Bombardieri, S., Hepatitis C virus and mixed cryoglobulinaemia. Eur J Clin Invest 23 (1993), 399–405.
22. [22] Zignego, A.L., Gragnani, L., Giannini, C., Laffi, G., The hepatitis C virus infection as a systemic disease. Intern Emerg Med 7:Suppl. 3 (2012), S201–S208.
23. [23] Lidar, M., Lipschitz, N., Agmon-Levin, N., Langevitz, P., Barzilai, O., Ram, M., et al. Infectious serologies and autoantibodies in hepatitis C and autoimmune disease-associated mixed cryoglobulinemia. Clin Rev Allergy Immunol 42 (2012), 238–246.
24. [24] Peveling-Oberhag, J., Arcaini, L., Bankov, K., Zeuzem, S., Herrmann, E., The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis. J Viral Hepat 23 (2016), 536–544.
25. [25] Zignego, A.L., Giannini, C., Gragnani, L., HCV and lymphoproliferation. Clin Dev Immunol, 2012, 2012, 980942.
26. [26] Zignego, A.L., Gragnani, L., Piluso, A., Sebastiani, M., Giuggioli, D., Fallahi, P., et al. Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. Expert Rev Clin Immunol 11 (2015), 15–31.
27. [27] Sene, D., Ghillani-Dalbin, P., Thibault, V., Guis, L., Musset, L., Duhaut, P., et al. Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. J Rheumatol 31 (2004), 2199–2206.
28. [28] Ferri, C., Marzo, E., Longombardo, G., Lombardini, F., La Civita, L., Vanacore, R., et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 81 (1993), 1132–1136.
29. [29] Marcellin, P., Descamps, V., Martinot-Peignoux, M., Larzul, D., Xu, L., Boyer, N., et al. Cryoglobulinemia with vasculitis associated with hepatitis C virus infection. Gastroenterology 104 (1993), 272–277.
30. [30] Johnson, R.J., Gretch, D.R., Yamabe, H., Hart, J., Bacchi, C.E., Hartwell, P., et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328 (1993), 465–470.
31. [31] Joshi, S., Kuczynski, M., Heathcote, E.J., Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulimia. Dig Dis Sci 52 (2007), 2410–2417.
32. [32] Landau, D.A., Saadoun, D., Halfon, P., Martinot-Peignoux, M., Marcellin, P., Fois, E., et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 58 (2008), 604–611.
33. [33] Montalbano, M., Pasulo, L., Sonzogni, A., Remuzzi, G., Colledan, M., Strazzabosco, M., Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol 41 (2007), 216–220.
34. [34] Garini, G., Allegri, L., Lannuzzella, F., Vaglio, A., Buzio, C., HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. Acta Biomed 78 (2007), 51–59.
35. [35] Cacoub, P., Lidove, O., Maisonobe, T., Duhaut, P., Thibault, V., Ghillani, P., et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 46 (2002), 3317–3326.
36. [36] Mazzaro, C., Zorat, F., Comar, C., Nascimben, F., Bianchini, D., Baracetti, S., et al. Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. J Rheumatol 30 (2003), 1775–1781.
37. [37] Pietrogrande, M., De Vita, S., Zignego, A.L., Pioltelli, P., Sansonno, D., Sollima, S., et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 10 (2011), 444–454.
38. [38] Saadoun, D., Resche Rigon, M., Pol, S., Thibault, V., Blanc, F., Pialoux, G., et al. PegIFNalpha/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol 62 (2015), 24–30.
39. [39] Gragnani, L., Fabbrizzi, A., Triboli, E., Urraro, T., Boldrini, B., Fognani, E., et al. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. Dig Liver Dis 46 (2014), 833–837.
40. [40] Stine, J.G., Cornella, S., Shah, N.L., Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir. Ann Rheum Dis, 73, 2014, e64.
41. [41] Cornella, S.L., Stine, J.G., Kelly, V., Caldwell, S.H., Shah, N.L., Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a case series. Postgrad Med 127 (2015), 413–417.
42. [42] Saadoun, D., Thibault, V., Si Ahmed, S.N., Alric, L., Mallet, M., Guillaud, C., et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis, 2015.
43. [43] Sise, M.E., Bloom, A.K., Wisocky, J., Lin, M.V., Gustafson, J.L., Lundquist, A.L., et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 63 (2016), 408–417.
44. [44] Gragnani, L., Piluso, A., Urraro, T., Fabbrizzi, A., Fognani, E., Petraccia, L., et al. Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study. Curr Drug Targets, 2016.
45. [45] Gragnani, L., Piluso, A., Urraro, T., Fabbrizzi, A., Fognani, E., Petraccia, L., et al. Virological and clinical response in patients with HCV-related mixed cryoglobulinemia treated with interferon-free regimens: preliminary results of a prospective pilot study. Hepatology, 62, 2015, 798a-a.
46. [46] Gragnani, L., Visentini, M., Fognani, E., Urraro, T., De Santis, A., Petraccia, L., et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology 64 (2016), 1473–1482.
47. [47] Bonacci, M., Lens, S., Londono, M.C., Marino, Z., Cid, M.C., Ramos-Casals, M., et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol, 2016.
48. [48] Hegazy, M.T., Hussein, M.A., Quartuccio, L., Fawzy, M., Zoheir, N., Ellawindi, M.I., et al. Treatment of cryoglobulinemic vasculitis with sofosbuvir in four combination protocols. Arthritis Rheum, 68(Suppl. 10), 2016.
49. [49] Kondili LA, W.L., Mallano, A., Fucili, L., Massella, M., Vinci, M., et al. HCVrelated mixed cryoglobulinemia: data from PITER, a nationwide italian HCV cohort study. J Hepatol, S618, 2016.
50. [50] Mazzaro, C., Panarello, G., Carniello, S., Faelli, A., Mazzi, G., Crovatto, M., et al. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Dig Liver Dis 32 (2000), 708–715.
51. [51] Dammacco, F., Sansonno, D., Han, J.H., Shyamala, V., Cornacchiulo, V., Iacobelli, A.R., et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 84 (1994), 3336–3343.
52. [52] Vacca, A., Felli, M.P., Farina, A.R., Martinotti, S., Maroder, M., Screpanti, I., et al. Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 175 (1992), 637–646.
53. [53] De Vecchi, A., Montagnino, G., Pozzi, C., Tarantino, A., Locatelli, F., Ponticelli, C., Intravenous methylprednisolone pulse therapy in essential mixed cryoglobulinemia nephropathy. Clin Nephrol 19 (1983), 221–227.
54. [54] Caviglia, A.G., Monti, G., Navassa, G., Colzani, M., Gomitoni, A., Villa, P., et al. Chronic-relapsing polyneuropathy in the course of cryoglobulinemia. Clinical aspects and plasmapheretic treatment. Ric Clin Lab 16 (1986), 385–387.
55. [55] Pioltelli, P., Maldifassi, P., Vacca, A., Mazzaro, C., Mussini, C., Migliaresi, S., et al. GISC protocol experience in the treatment of essential mixed cryoglobulinaemia. Clin Exp Rheumatol 13:Suppl. 13 (1995), S187–S190.
56. [56] Ferri, C., Sebastiani, M., Giuggioli, D., Cazzato, M., Longombardo, G., Antonelli, A., et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 33 (2004), 355–374.
57. [57] Terrier, B., Semoun, O., Saadoun, D., Sene, D., Resche-Rigon, M., Cacoub, P., Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum 63 (2011), 1748–1757.
58. [58] Monti, G., Saccardo, F., Rinaldi, G., Petrozzino, M.R., Gomitoni, A., Invernizzi, F., Colchicine in the treatment of mixed cryoglobulinemia. Clin Exp Rheumatol 13:Suppl. 13 (1995), S197–S199.
59. [59] Invernizzi, F., Monti, G., Colchicine and mixed cryoglobulinemia. Arthritis Rheum 36 (1993), 722–723.
60. [60] Ferri, C., Pietrogrande, M., Cecchetti, R., Tavoni, A., Cefalo, A., Buzzetti, G., et al. Low-antigen-content diet in the treatment of patients with mixed cryoglobulinemia. Am J Med 87 (1989), 519–524.
61. [61] Urraro, T., Gragnani, L., Piluso, A., Fabbrizzi, A., Monti, M., Fognani, E., et al. Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy. Case Rep Immunol, 2015, 2015, 816424.
62. [62] Zaja, F., De Vita, S., Mazzaro, C., Sacco, S., Damiani, D., De Marchi, G., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101 (2003), 3827–3834.
63. [63] Sansonno, D., De Re, V., Lauletta, G., Tucci, F.A., Boiocchi, M., Dammacco, F., Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101 (2003), 3818–3826.
64. [64] Roccatello, D., Baldovino, S., Rossi, D., Mansouri, M., Naretto, C., Gennaro, M., et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19 (2004), 3054–3061.
65. [65] Visentini, M., Granata, M., Veneziano, M.L., Borghese, F., Carlesimo, M., Pimpinelli, F., et al. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 125 (2007), 30–33.
66. [66] Quartuccio, L., Soardo, G., Romano, G., Zaja, F., Scott, C.A., De Marchi, G., et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 45 (2006), 842–846.
67. [67] Pekow, J., Chung, R.T., Treatment of type II cryoglobulinemia associated with hepatitis C with rituximab. J Clin Gastroenterol, 40, 2006, 450.
68. [68] Basse, G., Ribes, D., Kamar, N., Mehrenberger, M., Esposito, L., Guitard, J., et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 80 (2005), 1560–1564.
69. [69] Quartuccio, L., Petrarca, A., Mansutti, E., Pieroni, S., Calcabrini, L., Avellini, C., et al. Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia. Clin Exp Rheumatol 28 (2010), 84–87.
70. [70] Terrier, B., Saadoun, D., Sene, D., Sellam, J., Perard, L., Coppere, B., et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum 60 (2009), 2531–2540.
71. [71] Lamprecht, P., Lerin-Lozano, C., Merz, H., Dennin, R.H., Gause, A., Voswinkel, J., et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 62 (2003), 1230–1233.
72. [72] Bestard, O., Cruzado, J.M., Ercilla, G., Goma, M., Torras, J., Seron, D., et al. Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft. Nephrol Dial Transplant 21 (2006), 2320–2324.
73. [73] Korte, M.R., van Heerde, M.J., de Man, R.A., Betjes, M.H., Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia. Neth J Med 66 (2008), 27–30.
74. [74] Evans, J.T., Shepard, M.M., Oates, J.C., Self, S.E., Reuben, A., Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol 42 (2008), 862–863.
75. [75] Cavallo, R., Roccatello, D., Menegatti, E., Naretto, C., Napoli, F., Baldovino, S., Rituximab in cryoglobulinemic peripheral neuropathy. J Neurol 256 (2009), 1076–1082.
76. [76] Braun, A., Neumann, T., Oelzner, P., Hein, G., Grone, H.J., Ziemer, M., et al. Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab. Rheumatol Int 28 (2008), 503–506.
77. [77] Petrarca, A., Rigacci, L., Monti, M., Giannini, C., Bernardi, F., Caini, P., et al. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. Dig Liver Dis 39:Suppl. 1 (2007), S129–S133.
78. [78] Petrarca, A., Rigacci, L., Caini, P., Colagrande, S., Romagnoli, P., Vizzutti, F., et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 116 (2010), 335–342.
79. [79] Cabibbo, S., Antolino, A., Garozzo, G., Manenti, G.O., Bonomo, P., Clinical improvement induced by rituximab in two cases of type II mixed cryoglobulinaemia syndrome unresponsive to conventional treatments. Blood Transfus 8 (2010), 196–198.
80. [80] Uppal, R., Charles, E., Lake-Bakaar, G., Acute wrist and foot drop associated with hepatitis C virus related mixed cryoglobulinemia: rapid response to treatment with rituximab. J Clin Virol 47 (2010), 69–71.
81. [81] Visentini, M., Tinelli, C., Colantuono, S., Monti, M., Ludovisi, S., Gragnani, L., et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review. Autoimmun Rev 14 (2015), 889–896.
82. [82] Saadoun, D., Rosenzwajg, M., Landau, D., Piette, J.C., Klatzmann, D., Cacoub, P., Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 111 (2008), 5334–5341.
83. [83] De Vita, S., Quartuccio, L., Rituximab monotherapy, rather than rituximab plus antiviral drugs, for initial treatment of severe hepatitis C virus-associated mixed cryoglobulinemia syndrome: comment on the article by Terrier et al. Arthritis Rheum 62 (2010), 908–909 [author reply 9].
84. [84] De Vita, S., Quartuccio, L., Fabris, M., Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both?. Autoimmun Rev 8 (2008), 95–99.
85. [85] Saadoun, D., Resche Rigon, M., Sene, D., Terrier, B., Karras, A., Perard, L., et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 116 (2010), 326–334 [quiz 504-5].
86. [86] Dammacco, F., Tucci, F.A., Lauletta, G., Gatti, P., De Re, V., Conteduca, V., et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 116 (2010), 343–353.
87. [87] Ignatova, T., Chernova, O., Novikov, P., Moiseev, S., HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab?. Ann Rheum Dis, 73, 2014, e58.
88. [88] Saadoun D, Cacoub P. HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova et al Ann Rheum Dis 2014;73:e59.
89. [89] Ferri, C., La Civita, L., Caracciolo, F., Zignego, A.L., Non-Hodgkin's lymphoma: possible role of hepatitis C virus [letter]. JAMA 272 (1994), 355–356.
90. [90] Ferri, C., Caracciolo, F., Zignego, A.L., La Civita, L., Monti, M., Longombardo, G., et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol 88 (1994), 392–394.
91. [91] Zuckerman, E., Zuckerman, T., Levine, A.M., Douer, D., Gutekunst, K., Mizokami, M., et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 127 (1997), 423–428.
92. [92] de Sanjose, S., Benavente, Y., Vajdic, C.M., Engels, E.A., Morton, L.M., Bracci, P.M., et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 6 (2008), 451–458.
93. [93] Hausfater, P., Cacoub, P., Sterkers, Y., Thibault, V., Amoura, Z., Nguyen, L., et al. Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France. Am J Hematol 67 (2001), 168–171.
94. [94] Gisbert, J.P., Garcia-Buey, L., Pajares, J.M., Moreno-Otero, R., Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 125 (2003), 1723–1732.
95. [95] Matsuo, K., Kusano, A., Sugumar, A., Nakamura, S., Tajima, K., Mueller, N.E., Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 95 (2004), 745–752.
96. [96] Negri, E., Little, D., Boiocchi, M., La Vecchia, C., Franceschi, S., B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 111 (2004), 1–8.
97. [97] Dal Maso, L., Franceschi, S., Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 15 (2006), 2078–2085.
98. [98] Mele, A., Pulsoni, A., Bianco, E., Musto, P., Szklo, A., Sanpaolo, M.G., et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 102 (2003), 996–999.
99. [99] Marcucci, F., Mele, A., Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 117 (2011), 1792–1798.
100. [100] Hermine, O., Lefrere, F., Bronowicki, J.P., Mariette, X., Jondeau, K., Eclache-Saudreau, V., et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347 (2002), 89–94.
101. [101] Merli, M., Carli, G., Arcaini, L., Visco, C., Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. World J Gastroenterol 22 (2016), 8447–8458.
102. [102] Arcaini, L., Rossi, D., Paulli, M., Splenic marginal zone lymphoma: from genetics to management. Blood 127 (2016), 2072–2081.
103. [103] Torres, H.A., Mahale, P., Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization. Liver Int 35 (2015), 1661–1664.
104. [104] Dreyling, M., Thieblemont, C., Gallamini, A., Arcaini, L., Campo, E., Hermine, O., et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 24 (2013), 857–877.
105. [105] Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, et al. Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Netw 2013;11:257-72; [quiz 73].
106. [106] EASL, Clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 60 (2014), 392–420.
107. [107] Merli, M., Visco, C., Spina, M., Luminari, S., Ferretti, V.V., Gotti, M., et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica 99 (2014), 489–496.
108. [108] Tilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A., et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:Suppl. 5 (2015), v116–v125.
109. [109] Ennishi, D., Maeda, Y., Niitsu, N., Kojima, M., Izutsu, K., Takizawa, J., et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 116 (2010), 5119–5125.
110. [110] Musto, P., Dell'Olio, M., La Sala, A., Mantuano, S., Cascavilla, N., Diffuse B-large cell lymphomas (DBLCL) with hepatitis-C virus (HCV) infection: clinical outcome and preliminary results of a pilot study combining R-CHOP with antiviral therapy. Blood, 106, 2005, 688a-a.
111. [111] Michot, J.M., Canioni, D., Driss, H., Alric, L., Cacoub, P., Suarez, F., et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol 90 (2015), 197–203.
112. [112] Carrier, P., Jaccard, A., Jacques, J., Tabouret, T., Debette-Gratien, M., Abraham, J., et al. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int 35 (2015), 2222–2227.
113. [113] Kyvernitakis, A., Mahale, P., Popat, U.R., Jiang, Y., Hosry, J., Champlin, R.E., et al. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biol Blood Marrow Transplant 22 (2016), 717–722.
114. [114] Locasciulli, A., Bruno, B., Alessandrino, E.P., Meloni, G., Arcese, W., Bandini, G., et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 31 (2003), 295–300.
115. [115] Varma, A., Saliba, R.M., Torres, H.A., Afrough, A., Hosing, C., Khouri, I.F., et al. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplant, 2016.
116. [116] Butt, A.A., Wang, X., Fried, L.F., HCV infection and the incidence of CKD. Am J Kidney Dis 57 (2011), 396–402.
117. [117] Fabrizi, F., Poordad, F.F., Martin, P., Hepatitis C infection and the patient with end-stage renal disease. Hepatology 36 (2002), 3–10.
118. [118] El-Serag, H.B., Hampel, H., Yeh, C., Rabeneck, L., Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 36 (2002), 1439–1445.
119. [119] Dalrymple, L.S., Koepsell, T., Sampson, J., Louie, T., Dominitz, J.A., Young, B., et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol 2 (2007), 715–721.
120. [120] Wyatt, C.M., Malvestutto, C., Coca, S.G., Klotman, P.E., Parikh, C.R., The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS 22 (2008), 1799–1807.
121. [121] Lee, J.J., Lin, M.Y., Yang, Y.H., Lu, S.N., Chen, H.C., Hwang, S.J., Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis 56 (2010), 23–31.
122. [122] Roccatello, D., Fornasieri, A., Giachino, O., Rossi, D., Beltrame, A., Banfi, G., et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 49 (2007), 69–82.
123. [123] Alpers, C., Bloom, R.D., Fabrizi, F., Izopet, J., Jadoul, M., Lindley, E., et al. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease - introduction. Kidney Int 73 (2008), S6–S99.
124. [124] Cacoub, P., Desbois, A.C., Isnard-Bagnis, C., Rocatello, D., Ferri, C., Hepatitis C virus infection and chronic kidney disease: time for reappraisal. J Hepatol 65 (2016), S82–S94.
125. [125] Scarpato, S., Tirri, E., Naclerio, C., Moscato, P., Salvati, G., Plasmapheresis in cryoglobulinemic neuropathy: a clinical study. Dig Liver Dis 39:Suppl. 1 (2007), S136–S137.
126. [126] Sene, D., Ghillani-Dalbin, P., Amoura, Z., Musset, L., Cacoub, P., Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 60 (2009), 3848–3855.
127. [127] Roccatello, D., Sciascia, S., Baldovino, S., Rossi, D., Alpa, M., Naretto, C., et al. Improved (4 Plus 2) rituximab protocol for severe cases of mixed cryoglobulinemia: a 6-year observational study. Am J Nephrol 43 (2016), 251–260.
128. [128] Ye, J., Wang, C., Sumpter, R. Jr., Brown, M.S., Goldstein, J.L., Gale, M. Jr., Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 100 (2003), 15865–15870.
129. [129] Ashrafi, M., Modabbernia, A., Dalir, M., Taslimi, S., Karami, M., Ostovaneh, M.R., et al. Predictors of mental and physical health in non-cirrhotic patients with viral hepatitis: a case control study. J Psychosom Res 73 (2012), 218–224.
130. [130] Sockalingam, S., Abbey, S.E., Alosaimi, F., Novak, M., A review of sleep disturbance in hepatitis C. J Clin Gastroenterol 44 (2010), 38–45.
131. [131] Poynard, T., Cacoub, P., Ratziu, V., Myers, R.P., Dezailles, M.H., Mercadier, A., et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 9 (2002), 295–303.
132. [132] Monaco, S., Mariotto, S., Ferrari, S., Calabrese, M., Zanusso, G., Gajofatto, A., et al. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: advances in 2015. World J Gastroenterol 21 (2015), 11974–11983.
133. [133] Kallman, J., O'Neil, M.M., Larive, B., Boparai, N., Calabrese, L., Younossi, Z.M., Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 52 (2007), 2531–2539.
134. [134] Solinas, A., Piras, M.R., Deplano, A., Cognitive dysfunction and hepatitis C virus infection. World J Hepatol 7 (2015), 922–925.
135. [135] Lowry, D., Coughlan, B., McCarthy, O., Crowe, J., Investigating health-related quality of life, mood and neuropsychological test performance in a homogeneous cohort of Irish female hepatitis C patients. J Viral Hepat 17 (2010), 352–359.
136. [136] Forton, D.M., Thomas, H.C., Murphy, C.A., Allsop, J.M., Foster, G.R., Main, J., et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 35 (2002), 433–439.
137. [137] McAndrews, M.P., Farcnik, K., Carlen, P., Damyanovich, A., Mrkonjic, M., Jones, S., et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 41 (2005), 801–808.
138. [138] Wilkinson, J., Radkowski, M., Laskus, T., Hepatitis C virus neuroinvasion: identification of infected cells. J Virol 83 (2009), 1312–1319.
139. [139] Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 57 (2012), 1379–1390.
140. [140] Laskus, T., Radkowski, M., Adair, D.M., Wilkinson, J., Scheck, A.C., Rakela, J., Emerging evidence of hepatitis C virus neuroinvasion. AIDS 19:Suppl. 3 (2005), S140–S144.
141. [141] Martinez, R.M., Zarpelon, A.C., Cardoso, R.D., Vicentini, F.T., Georgetti, S.R., Baracat, M.M., et al. Tephrosia sinapou ethyl acetate extract inhibits inflammatory pain in mice: opioid receptor dependent inhibition of TNFalpha and IL-1beta production. Pharm Biol 51 (2013), 1262–1271.
142. [142] Palin, K., Bluthe, R.M., McCusker, R.H., Moos, F., Dantzer, R., Kelley, K.W., TNFalpha-induced sickness behavior in mice with functional 55 kD TNF receptors is blocked by central IGF-I. J Neuroimmunol 187 (2007), 55–60.
143. [143] Cozzi, A., Zignego, A.L., Carpendo, R., Biagiotti, T., Aldinucci, A., Monti, M., et al. Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J Viral Hepat 13 (2006), 402–408.
144. [144] Casato, M., Saadoun, D., Marchetti, A., Limal, N., Picq, C., Pantano, P., et al. Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis: a multicenter case-control study using magnetic resonance imaging and neuropsychological tests. J Rheumatol 32 (2005), 484–488.
145. [145] Bonkovsky, H.L., Woolley, J.M., Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 29 (1999), 264–270.
146. [146] Bonkovsky, H.L., Snow, K.K., Malet, P.F., Back-Madruga, C., Fontana, R.J., Sterling, R.K., et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 46 (2007), 420–431.
147. [147] Kang, S.C., Hwang, S.J., Lee, S.H., Chang, F.Y., Lee, S.D., Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World J Gastroenterol 11 (2005), 7494–7498.
148. [148] Younossi, Z., Kallman, J., Kincaid, J., The effects of HCV infection and management on health-related quality of life. Hepatology 45 (2007), 806–816.
149. [149] McHutchison, J.G., Ware, J.E. Jr., Bayliss, M.S., Pianko, S., Albrecht, J.K., Cort, S., et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 34 (2001), 140–147.
150. [150] Spiegel, B.M., Younossi, Z.M., Hays, R.D., Revicki, D., Robbins, S., Kanwal, F., Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 41 (2005), 790–800.
151. [151] Raison, C.L., Borisov, A.S., Broadwell, S.D., Capuron, L., Woolwine, B.J., Jacobson, I.M., et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 66 (2005), 41–48.
152. [152] Vignau, J., Karila, L., Costisella, O., Canva, V., Hepatitis C, interferon a and depression: main physiopathologic hypothesis. Encéphale 31 (2005), 349–357.
153. [153] Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M.A., Hill, J., et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 7 (2002), 942–947.
154. [154] Younossi, Z.M., Stepanova, M., Zeuzem, S., Dusheiko, G., Esteban, R., Hezode, C., et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol 61 (2014), 228–234.
155. [155] Modabbernia, A., Poustchi, H., Malekzadeh, R., Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review. Hepat Mon, 13, 2013, e8340.
156. [156] Isaacs, D., Abdelaziz, N., Keller, M., Tibble, J., Haq, I., Measuring the response of extrahepatic symptoms and quality of life to antiviral treatment in patients with hepatitis C. Hepat Res Treat, 2013, 2013, 910519.
157. [157] Younossi, Z.M., Stepanova, M., Marcellin, P., Afdhal, N., Kowdley, K.V., Zeuzem, S., et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology 61 (2015), 1798–1808.
158. [158] Younossi, Z., Henry, L., Systematic review: patient-reported outcomes in chronic hepatitis C—the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 41 (2015), 497–520.
159. [159] Rowan, P.J., Bhulani, N., Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments. World J Hepatol 7 (2015), 2209–2213.
160. [160] Cacoub, P., Poynard, T., Ghillani, P., Charlotte, F., Olivi, M., Piette, J.C., et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 42 (1999), 2204–2212.
161. [161] Fernandez, I., Castellano, G., de Salamanca, R.E., Colina, F., Gomez de la Camara, A., Moran, M.J., et al. Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. Scand J Gastroenterol 38 (2003), 314–319.
162. [162] Desai, T.K., Jamil, L.H., Balasubramaniam, M., Koff, R., Bonkovsky, H.L., Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci 53 (2008), 815–822.
163. [163] Garcovich, S., Garcovich, M., Capizzi, R., Gasbarrini, A., Zocco, M.A., Cutaneous manifestations of hepatitis C in the era of new antiviral agents. World J Hepatol 7 (2015), 2740–2748.
164. [164] Gisbert, J.P., Garcia-Buey, L., Pajares, J.M., Moreno-Otero, R., Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 39 (2003), 620–627.
165. [165] Azim, J., McCurdy, H., Moseley, R.H., Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C. World J Gastroenterol 14 (2008), 5913–5915.
166. [166] Le Cleach, L., Chosidow, O., Clinical practice. Lichen planus. N Engl J Med 366 (2012), 723–732.
167. [167] Shengyuan, L., Songpo, Y., Wen, W., Wenjing, T., Haitao, Z., Binyou, W., Hepatitis C virus and lichen planus: a reciprocal association determined by a meta-analysis. Arch Dermatol 145 (2009), 1040–1047.
168. [168] Carbone, T., Nasorri, F., Pennino, D., Donnarumma, M., Garcovich, S., Eyerich, K., et al. CD56 highCD16 - NK cell involvement in cutaneous lichen planus. Eur J Dermatol 20 (2010), 724–730.
169. [169] Sontheimer, R.D., Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives. J Invest Dermatol 129 (2009), 1088–1099.
170. [170] Dalekos, G.N., Christodoulou, D., Kistis, K.G., Zervou, E.K., Hatzis, J., Tsianos, E.V., A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 10 (1998), 933–939.
171. [171] Manousaridis, I., Manousaridis, K., Peitsch, W.K., Schneider, S.W., Individualizing treatment and choice of medication in lichen planus: a step by step approach. J Dtsch Dermatol Ges 11 (2013), 981–991.
172. [172] Cheng, S., Kirtschig, G., Cooper, S., Thornhill, M., Leonardi-Bee, J., Murphy, R., Interventions for erosive lichen planus affecting mucosal sites. Cochrane Database Syst Rev, 2012, CD008092.
173. [173] Fallahi, P., Ferrari, S.M., Politti, U., Giuggioli, D., Ferri, C., Antonelli, A., Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection. Int J Endocrinol, 2014, 2014, 935131.
174. [174] Shen, Y., Wang, X.L., Xie, J.P., Shao, J.G., Lu, Y.H., Zhang, S., et al. Thyroid disturbance in patients with chronic hepatitis C infection: a systematic review and meta-analysis. J Gastrointestin Liver Dis 25 (2016), 227–234.
175. [175] Fallahi, P., Ferrari, S.M., Ruffilli, I., Elia, G., Giuggioli, D., Colaci, M., et al. Incidence of thyroid disorders in mixed cryoglobulinemia: results from a longitudinal follow-up. Autoimmun Rev 15 (2016), 747–751.
176. [176] Mao, X.R., Zhang, L.T., Chen, H., Xiao, P., Zhang, Y.C., Possible factors affecting thyroid dysfunction in hepatitis C virus-infected untreated patients. Exp Ther Med 8 (2014), 133–140.
177. [177] Antonelli, A., Ferri, C., Fallahi, P., Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy. Nat Rev Gastroenterol Hepatol 6 (2009), 633–635.
178. [178] Mammen, J.S., Ghazarian, S.R., Rosen, A., Ladenson, P.W., Patterns of interferon-alpha-induced thyroid dysfunction vary with ethnicity, sex, smoking status, and pretreatment thyrotropin in an international cohort of patients treated for hepatitis C. Thyroid 23 (2013), 1151–1158.
179. [179] Czarnywojtek, A., Zgorzalewicz-Stachowiak, M., Wasko, R., Czepczynski, R., Szczepanek-Parulska, E., Waligorska-Stachura, J., et al. Patients with chronic hepatitis type C and interferon-alpha-induced hyperthyroidism in two-years clinical follow-up. Neuro Endocrinol Lett 34 (2013), 154–161.
180. [180] Minelli, R., Spagnoli, F., Marchesi, E., Venturi, N., Marina, M., Orlandini, A., et al. Course of graves disease in interferon-treated patients with chronic hepatitis C virus infection and in uninfected patients. J Invest Med 61 (2013), 1173–1177.
181. [181] Nair Kesavachandran, C., Haamann, F., Nienhaus, A., Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One, 8, 2013, e55364.
182. [182] Antonelli, A., Ferri, C., Fallahi, P., Ferrari, S.M., Frascerra, S., Sebastiani, M., et al. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine 42 (2008), 137–143.
183. [183] Zhang, R.W., Shao, C.P., Huo, N., Li, M.R., Xi, H.L., Yu, M., et al. Thyroid dysfunction in Chinese hepatitis C patients: prevalence and correlation with TPOAb and CXCL10. World J Gastroenterol 21 (2015), 9765–9773.
184. [184] El Raziky, M., Fathalah, W.F., Zakaria, Z., Eldeen, H.G., Abul-Fotouh, A., Salama, A., et al. Predictors of virological response in 3,235 chronic HCV Egyptian patients treated with peginterferon alpha-2a compared with peginterferon alpha-2b using statistical methods and data mining techniques. J Interferon Cytokine Res 36 (2016), 338–346.
185. [185] Vita, R., Fallahi, P., Antonelli, A., Benvenga, S., The administration of L-thyroxine as soft gel capsule or liquid solution. Expert Opin Drug Deliv 11 (2014), 1103–1111.
186. [186] Honer Zu Siederdissen, C., Maasoumy, B., Marra, F., Deterding, K., Port, K., Manns, M.P., et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis 62 (2016), 561–567.
187. [187] Antonelli, A., Ferrari, S.M., Corrado, A., Di Domenicantonio, A., Fallahi, P., Autoimmune thyroid disorders. Autoimmun Rev 14 (2015), 174–180.
188. [188] Mehta, S.H., Brancati, F.L., Sulkowski, M.S., Strathdee, S.A., Szklo, M., Thomas, D.L., Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133 (2000), 592–599.
189. [189] Younossi, Z., Park, H., Henry, L., Adeyemi, A., Stepanova, M., Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 150 (2016), 1599–1608.
190. [190] Konishi, I., Horiike, N., Hiasa, Y., Tokumoto, Y., Mashiba, T., Michitaka, K., et al. Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Hepatol Res 37 (2007), 331–336.
191. [191] Elgouhari, H.M., Zein, C.O., Hanouneh, I., Feldstein, A.E., Zein, N.N., Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci 54 (2009), 2699–2705.
192. [192] Saeed, M.J., Olsen, M.A., Powderly, W.G., Presti, R.M., Diabetes mellitus is associated with higher risk of developing decompensated cirrhosis in chronic hepatitis C patients. J Clin Gastroenterol, 2016.
193. [193] Lai, M.S., Hsieh, M.S., Chiu, Y.H., Chen, T.H., Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 43 (2006), 1295–1302.
194. [194] Bose, S.K., Ray, R., Hepatitis C virus infection and insulin resistance. World J Diabetes 5 (2014), 52–58.
195. [195] Romero-Gomez, M., Del Mar, Viloria M., Andrade, R.J., Salmeron, J., Diago, M., Fernandez-Rodriguez, C.M., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128 (2005), 636–641.
196. [196] Goossens, N., Negro, F., The impact of obesity and metabolic syndrome on chronic hepatitis C. Clin Liver Dis 18 (2014), 147–156.
197. [197] Kralj, D., Virovic Jukic, L., Stojsavljevic, S., Duvnjak, M., Smolic, M., Curcic, I.B., Hepatitis C virus, insulin resistance, and steatosis. J Clin Transl Hepatol 4 (2016), 66–75.
198. [198] Domont, F., Cacoub, P., Chronic hepatitis C virus infection, a new cardiovascular risk factor?. Liver Int 36 (2016), 621–627.
199. [199] Crook, E.D., Penumalee, S., Gavini, B., Filippova, K., Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care 28 (2005), 2187–2191.
200. [200] Konrad, T., Zeuzem, S., Vicini, P., Toffolo, G., Briem, D., Lormann, J., et al. Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur J Clin Invest 30 (2000), 111–121.
201. [201] Vanni, E., Bugianesi, E., Saracco, G., Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?. Dig Liver Dis 48 (2016), 105–111.
202. [202] Pashun, R.A., Shen, N.T., Jesudian, A., Markedly improved glycemic control in poorly controlled type 2 diabetes following direct acting antiviral treatment of genotype 1 hepatitis C. Case Rep Hepatol, 2016, 2016, 7807921.
203. [203] Wynter, J., Stine, J.G., Shah, N.L., Chronic hepatitis C and diabetes: more questions than answers with the new direct acting antiviral drugs?. Dig Liver Dis, 2016.
204. [204] Younossi, Z.M., Stepanova, M., Chan, H.L., Lee, M.H., Yu, M.L., Dan, Y.Y., et al. Patient-reported outcomes in Asian patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine (Baltimore), 95, 2016, e2702.
205. [205] Pattullo, V., Heathcote, J., Hepatitis C and diabetes: one treatment for two diseases?. Liver Int 30 (2010), 356–364.
206. [206] Kita, Y., Mizukoshi, E., Takamura, T., Sakurai, M., Takata, Y., Arai, K., et al. Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus. Metabolism 56 (2007), 1682–1688.
207. [207] Bressler, B.L., Guindi, M., Tomlinson, G., Heathcote, J., High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38 (2003), 639–644.
208. [208] Gunton, J.E., Delhanty, P.J., Takahashi, S., Baxter, R.C., Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab 88 (2003), 1323–1332.
209. [209] Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002), 393–403.
210. [210] Shaw, R.J., Lamia, K.A., Vasquez, D., Koo, S.H., Bardeesy, N., Depinho, R.A., et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 (2005), 1642–1646.
211. [211] Harris, K., Smith, L., Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. Ann Pharmacother 47 (2013), 1348–1352.
212. [212] O'Leary, J.G., Chan, J.L., McMahon, C.M., Chung, R.T., Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 45 (2007), 895–898.
213. [213] Henderson, L.M., Patel, S., Giordano, T.P., Green, L., El-Serag, H.B., Statin therapy and serum transaminases among a cohort of HCV-infected veterans. Dig Dis Sci 55 (2010), 190–195.
214. [214] Toussirot, E., Le Huede, G., Mougin, C., Balblanc, J.C., Bettinger, D., Wendling, D., Presence of hepatitis C virus RNA in the salivary glands of patients with Sjogren's syndrome and hepatitis C virus infection. J Rheumatol 29 (2002), 2382–2385.
215. [215] Koike, K., Moriya, K., Ishibashi, K., Yotsuyanagi, H., Shintani, Y., Fujie, H., et al. Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci U S A 94 (1997), 233–236.
216. [216] Cacoub, P., Renou, C., Rosenthal, E., Cohen, P., Loury, I., Loustaud-Ratti, V., et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 79 (2000), 47–56.
217. [217] Ramos-Casals, M., Garcia-Carrasco, M., Cervera, R., Gaya, J., Halperin, I., Ubieto, I., et al. Thyroid disease in primary Sjogren syndrome. Study in a series of 160 patients. Medicine (Baltimore) 79 (2000), 103–108.
218. [218] Ferri, C., Mixed cryoglobulinemia. Orphanet J Rare Dis, 3, 2008, 25.
219. [219] Doffoel-Hantz, V., Loustaud-Ratti, V., Ramos-Casals, M., Alain, S., Bezanahary, H., Liozon, E., et al. Evolution of Sjogren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin. Rev Med Interne 26 (2005), 88–94.
220. [220] Palazzi, C., D'Amico, E., D'Angelo, S., Gilio, M., Olivieri, I., Rheumatic manifestations of hepatitis C virus chronic infection: Indications for a correct diagnosis. World J Gastroenterol 22 (2016), 1405–1410.
221. [221] Palazzi, C., Olivieri, I., D'Amico, E., D'Agostino, L., Nicolucci, A., Pennese, E., et al. Hepatitis C virus infection in psoriatic arthritis. Arthritis Rheum 53 (2005), 223–225.
222. [222] Buskila, D., Shnaider, A., Neumann, L., Lorber, M., Zilberman, D., Hilzenrat, N., et al. Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. Semin Arthritis Rheum 28 (1998), 107–113.
223. [223] Rivera, J., Garcia-Monforte, A., Hepatitis C virus infection presenting as rheumatoid arthritis. Why not?. J Rheumatol 26 (1999), 2062–2063.
224. [224] Lovy, M.R., Starkebaum, G., Uberoi, S., Hepatitis C infection presenting with rheumatic manifestations: a mimic of rheumatoid arthritis. J Rheumatol 23 (1996), 979–983.
225. [225] Zuckerman, E., Keren, D., Rozenbaum, M., Toubi, E., Slobodin, G., Tamir, A., et al. Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol 18 (2000), 579–584.
226. [226] Fadda, P., La Civita, L., Zignego, A.L., Ferri, C., Hepatitis C virus infection and arthritis. A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome. Reumatismo 54 (2002), 316–323.
227. [227] Palazzi, C., D'Angelo, S., Olivieri, I., Hepatitis C virus-related arthritis. Autoimmun Rev 8 (2008), 48–51.
228. [228] Olivieri, I., Palazzi, C., Padula, A., Hepatitis C virus and arthritis. Rheum Dis Clin North Am 29 (2003), 111–122.
229. [229] Sene, D., Ghillani-Dalbin, P., Limal, N., Thibault, V., van Boekel, T., Piette, J.C., et al. Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjogren's syndrome. Ann Rheum Dis 65 (2006), 394–397.
230. [230] Bombardieri, M., Alessandri, C., Labbadia, G., Iannuccelli, C., Carlucci, F., Riccieri, V., et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther 6 (2004), R137–R141.
231. [231] Akhtar, A.J., Funnye, A.S., Hepatitis C virus associated arthritis in absence of clinical, biochemical and histological evidence of liver disease—responding to interferon therapy. Med Sci Monit 11 (2005), CS37–CS39.
232. [232] Palazzi, C., D'Amico, E., D'Angelo, S., Gilio, M., Leccese, P., Olivieri, I., An update on the management of hepatitis C virus-related arthritis. Expert Opin Pharmacother 15 (2014), 2039–2045.
233. [233] Ferri, C., Sebastiani, M., Antonelli, A., Colaci, M., Manfredi, A., Giuggioli, D., Current treatment of hepatitis C-associated rheumatic diseases. Arthritis Res Ther, 14, 2012, 215.
234. [234] Ferri, C., Cacoub, P., Mazzaro, C., Roccatello, D., Scaini, P., Sebastiani, M., et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 11 (2011), 48–55.
235. [235] Zimmermann, R., Konig, V., Bauditz, J., Hopf, U., Interferon alfa in leukocytoclastic vasculitis, mixed cryoglobulinaemia, and chronic hepatitis c. Lancet 341:8844 (1993), 561–562.
236. [236] Bojic, I., Lilic, D., Radojcic, C., Mijuskovic, P., deterioration of mixed cryoglobulinemia during treatment with interferon-alpha-2a. J Gastroenterol 29:3 (1994), 369–371.
237. [237] Johnson, R.J., Gretch, D.R., Couser, W.G., Alpers, C.E., Wilson, J., Chung, M., et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 46:6 (1994), 1700–1704.
238. [238] Mazzaro, C., Pozzato, G., Moretti, M., Crovatto, M., Modolo, M.L., Mazzi, G., et al. Long-term effects of alpha-interferon therapy for type II mixed cryoglobulinemia. Haematologica 79:4 (1994), 342–349.
239. [239] Gilli, P., Stabellini, N., Storari, A., Gualandi, G., Guerra, G., Ghinelli, F., Effect of human leukocyte alpha interferon on cryoglobulinaemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Nephrol Dial Transplant 11:3 (1996), 526–528.
240. [240] Harle, J.R., Disdier, P., Pelletier, J., Azulay, J.P., Perréard, M., Weiller, P.J., et al. Dramatic worsening of hepatitis C virus-related cryoglobulinemia subsequent to treatment with interferon alfa. JAMA, 274(2), 1995, 126.
241. [241] Mazzaro, C., Lacchin, T., Moretti, M., Tulissi, P., Manazzone, O., Colle, R., et al. Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia. Clin Exp Rheumatol 13:Suppl. 13 (1995), S181–S185.
242. [242] Migliaresi, S., Tirri, G., Interferon in the treatment of mixed cryoglobulinemia. Clin Exp Rheumatol 13:Suppl. 13 (1995), S175–S180.
243. [243] Yamabe, H., Inuma, H., Osawa, H., Kaizuka, M., Tamura, N., Tsunoda, S., et al. Glomerular deposition of hepatitis C virus in membranoproliferative glomerulonephritis. Nephron, 72(4), 1996, 741.
244. [244] Casaril, M., Capra, F., Gabrielli, G.B., Bassi, A., Squarzoni, S., Dagradi, R., et al. Cryoglobulinemia in hepatitis C virus chronic active hepatitis: effects of interferon-alpha therapy. J Interferon Cytokine Res 16:8 (1996), 585–588.
245. [245] Cohen, P., Nguyen, Q.T., Deny, P., Ferrière, F., Roulot, D., Lortholary, O., et al. Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patients. Ann Med Interne (Paris) 147:2 (1996), 81–86.
246. [246] Sarac, E., Bastacky, S., Johnson, J.P., Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection. Am J Kidney Dis 30:1 (1997), 113–115.
247. [247] Zuber, M., Gause, A., Peripheral neuropathy during interferon-alpha therapy in patients with cryoglobulinemia and hepatitis virus infection. J Rheumatol 24:12 (1997), 2488–2489.
248. [248] Akriviadis, E.A., Xanthakis, I., Navrozidou, C., Papadopoulos, A., Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alpha. J Clin Gastroenterol 25:4 (1997), 612–618.
249. [249] Casato, M., Agnello, V., Pucillo, L.P., Knight, G.B., Leoni, M., Del Vecchio, S., et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 90:10 (1997), 3865–3873.
250. [250] Mazzaro, C., Carniello, G.S., Colle, R., Doretto, P., Mazzi, G., Crovatto, M., et al. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy. Ital J Gastroenterol Hepatol 29:4 (1997), 343–350.
251. [251] Donada, C., Crucitti, A., Donadon, V., Chemello, L., Alberti, A., Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia. Blood 92:8 (1998), 2983–2984.
252. [252] Durand, J.M., Cacoub, P., Lunel-Fabiani, F., Cosserat, J., Cretel, E., Kaplanski, G., et al. Ribavirin in hepatitis C related cryoglobulinemia. J Rheumatol 25:6 (1998), 1115–1117.
253. [253] Gordon, A.C., Edgar, J.D., Finch, R.G., Acute exacerbation of vasculitis during interferon-alpha therapy for hepatitis C-associated cryoglobulinaemia. J Infect 36:2 (1998), 229–230.
254. [254] Scelsa, S.N., Herskovitz, S., Reichler, B., Treatment of mononeuropathy multiplex in hepatitis C virus and cryoglobulinemia. Muscle Nerve 21:11 (1998), 1526–1529.
255. [255] Calleja, J.L., Albillos, A., Moreno-Otero, R., Rossi, I., Cacho, G., Domper, F., et al. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther 13:9 (1999), 1179–1186.
256. [256] Cid, M.C., Hernandez-Rodriguez, J., Robert, J., del Río, A., Casademont, J., Coll-Vinent, B., et al. Interferon-alpha may exacerbate cryoblobulinemia-related ischemic manifestations: an adverse effect potentially related to its anti-angiogenic activity. Arthritis Rheum 42:5 (1999), 1051–1055.
257. [257] Cresta, P., Musset, L., Cacoub, P., Frangeul, L., Vitour, D., Poynard, T., et al. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut 45:1 (1999), 122–128.
258. [258] Friedman, G., Mehta, S., Sherker, A.H., Fatal exacerbation of hepatitis C-related cryoglobulinemia with interferon-alpha therapy. Dig Dis Sci 44:7 (1999), 1364–1365.
259. [259] Misiani, R., Bellavita, P., Baio, P., Caldara, R., Ferruzzi, S., Rossi, P., et al. Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin. Nephrol Dial Transplant 14:6 (1999), 1558–1560.
260. [260] Garini, G., Allegri, L., Carnevali, L., Catellani, W., Manganelli, P., Buzio, C., Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis, 38(6), 2001, E35.
261. [261] Naarendorp, M., Kallemuchikkal, U., Nuovo, G.J., Gorevic, P.D., Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 28:11 (2001), 2466–2473.
262. [262] Beddhu, S., Bastacky, S., Johnson, J.P., The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 81:5 (2002), 398–409.
263. [263] Casato, M., Mecucci, C., Agnello, V., Fiorilli, M., Knight, G.B., Matteucci, C., et al. Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. Blood 99:6 (2002), 2259–2261.
264. [264] Loustaud-Ratti, V., Liozon, E., Karaaslan, H., Alain, S., Paraf, F., Le Meur, Y., et al. Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection. Am J Med 113:6 (2002), 516–519.
265. [265] Sikaneta, T., Williams, W.W., Chung, R.T., Cosimi, A.B., Pascual, A.M., Remission of hepatitis C virus-associated cryoglobulinemic glomerulonephritis with interferon alfa-2b and ribavirin combination therapy after liver transplantation. Transplantation 74:12 (2002), 1767–1768.
266. [266] Bruchfeld, A., Lindahl, K., Stahle, L., Soderberg, M., Schvarcz, R., Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 18:8 (2003), 1573–1580.
267. [267] Rossi, P., Bertani, T., Baio, P., Caldara, R., Luliri, P., Tengattini, F., et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 63:6 (2003), 2236–2241.
268. [268] Alric, L., Plaisier, E., Thebault, S., Péron, J.M., Rostaing, L., Pourrat, J., et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 43:4 (2004), 617–623.
269. [269] Batisse, D., Karmochkine, M., Jacquot, C., Kazatchkine, M.D., Weiss, L., Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa. Eur J Gastroenterol Hepatol 16:7 (2004), 701–703.
270. [270] Cacoub, P., Saadoun, D., Limal, N., Sene, D., Lidove, O., Piette Jc. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 52:3 (2005), 911–915.
271. [271] Levine, J.W., Gota, C., Fessler, B.J., Calabrese, L.H., Cooper, S.M., Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 32:6 (2005), 1164–1167.
272. [272] Mazzaro, C., Zorat, F., Caizzi, M., Donada, C., Di Gennaro, G., Maso, L.D., et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 42:5 (2005), 632–638.
273. [273] Vigani, A.G., Macedo-De-Oliveira, A., Pavan, M.H., Pedro, M.N., Goncales, F.L. Jr., Hepatitis C virus infection, cryoglobulinemia, and peripheral neuropathy: a case report. Braz J Med Biol Res 38:12 (2005), 1729–1734.
274. [274] Saadoun, D., Resche-Rigon, M., Thibault, V., Piette, J.C., Cacoub, P., Antiviral therapy for hepatitis C virus—associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 54:11 (2006), 3696–3706.
275. [275] Parise, E.R., De Oliveira, A.C., Ferraz, M.L., Pereira, A.B., Leite, K.R., Cryoglobulinemia in chronic hepatitis C: clinical aspects and response to treatment with interferon alpha and ribavirin. Rev Inst Med Trop Sao Paulo 49:2 (2007), 67–72.
276. [276] Koziolek, M.J., Scheel, A., Bramlage, C., Groene, H.J., Mueller, G.A., Strutz, F., Effective treatment of hepatitis C-associated immune-complex nephritis with cryoprecipitate apheresis and antiviral therapy. Clin Nephrol 67:4 (2007), 245–249.
277. [277] Trebst, C., Wedemeyer, H., Manns, M.P., Tillmann, H., Windhagen, A., Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated interferon-alpha and ribavirin. Eur J Gastroenterol Hepatol 19:1 (2007), 91–92.
278. [278] De Blasi, T., Aguilar Marucco, D., Cariti, G., Maiello, A., De Rosa, F.G., Di Perri, G., Cryoglobulinemia-related vasculitis during effective anti-HCV treatment with PEG-interferon alfa-2b. Infection 36:3 (2008), 285–287.
279. [279] Landau, D.A., Rosenzwajg, M., Saadoun, D., Trebeden-Negre, H., Klatzmann, D., Cacoub, P., Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Arthritis Rheum 58:9 (2008), 2897–2907.
280. [280] Donato, M.F., Fabrizi, F., Fogazzi, G.B., Cresseri, D., Passerini, P., Martin, P., et al. Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review. Int J Artif Organs 36:1 (2013), 63–68.
281. [281] Saadoun, D., Resche Rigon, M., Thibault, V., Longuet, M., Pol, S., Blanc, F., et al. Peg-IFNalpha/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 73:5 (2014), 831–837.
282. [282] De Nicola, S., Aghemo, A., Campise, M.R., D'Ambrosio, R., Rumi, M.G., Messa, P., et al. Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis. Antivir Ther 19:5 (2014), 527–531.
283. [283] Sultanik, P., Klotz, C., Brault, P., Pol, S., Mallet, V., Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood 125:15 (2015), 2446–2447.
284. [284] Flemming, J.A., Lowe, C.E., Successful treatment of hepatitis C, genotype 3, with sofosbuvir/ledipasvir in decompensated cirrhosis complicated by mixed cryoglobulinaemia. BMJ Case Rep, 2016, 2016.
285. [285] Sollima, S., Milazzo, L., Peri, A.M., Torre, A., Antinori, S., Galli, M., Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. Rheumatology (Oxford), 2016.